{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:04Z","timestamp":1790746804635,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bone marrow (BM) fibrosis in primary and post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis (MF) has traditionally been considered a reactive process driven by cytokines, such as transforming growth factor \u03b21 (TGF-\u03b21), primarily produced by neoplastic megakaryocytes and platelets. These cytokines promote the differentiation of wild-type mesenchymal stromal cells into collagen- and fibronectin-producing myofibroblasts, thereby inducing BM fibrosis. However, hematopoietic-derived collagen-producing cells of monocyte lineage, termed fibrocytes, have also been implicated in this process. Here, we demonstrate that fibrocytes constitute a major collagen-producing cell population in the BM of patients with JAK2V617F-mutated MF, with additional contributions from myofibroblasts. Analysis of BM samples from patients with JAK2V617F-mutated myeloproliferative neoplasms (MPNs) revealed that fibrocytes accounted for nearly two-thirds of collagen-producing cells, whereas myofibroblasts represented a smaller subset. Using BM-derived fibrocytes from Jak2V617F transgenic mice (Jak2V617F mice), we performed a high-throughput drug screen and identified statins as inhibitors of fibrocyte proliferation in vitro. In vivo, pitavastatin treatment reduced fibrocyte numbers, ameliorated BM fibrosis, and improved anemia in Jak2V617F mice. Pitavastatin also decreased TGF-\u03b21 production by neoplastic fibrocytes, resulting in reduced myofibroblast expansion. Peripheral blood\u2013derived fibrocytes from patients with JAK2V617F-mutated MPNs were similarly sensitive to pitavastatin in vitro. Together, these findings suggest that fibrocytes substantially contribute to BM fibrosis in JAK2V617F-mutated MF and support further investigation of pitavastatin as a potential antifibrotic strategy in this molecular subset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032693","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:45:17Z","timestamp":1783028717000},"page":"1723-1736","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Fibrocytes drive\n                    <i>JAK2<\/i>\n                    V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4511-4901","authenticated-orcid":false,"given":"Taisuke","family":"Uchida","sequence":"first","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-3254","authenticated-orcid":false,"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-1710","authenticated-orcid":false,"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-5831","authenticated-orcid":false,"given":"Yoshinori","family":"Ozono","sequence":"additional","affiliation":[{"name":"2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-9136","authenticated-orcid":false,"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-4559","authenticated-orcid":false,"given":"Yuki","family":"Tahira","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-4305","authenticated-orcid":false,"given":"Ayako","family":"Kamiunten","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2302-4069","authenticated-orcid":false,"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[{"name":"3Division of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-3456","authenticated-orcid":false,"given":"Keiichi","family":"Akizuki","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Karasawa","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-4109","authenticated-orcid":false,"given":"Yudai","family":"Uehira","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-594X","authenticated-orcid":false,"given":"Hiroaki","family":"Ueno","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-7988","authenticated-orcid":false,"given":"Hideki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-8188","authenticated-orcid":false,"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026092411213140600_bib1","first-page":"47","volume-title":"WHO Classification of Haematolymphoid Tumours","author":"Kanagal-Shamanna","year":"2024","edition":"6th ed"},{"issue":"8","key":"2026092411213140600_bib2","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"2026092411213140600_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-92-6-857","article-title":"The pathogenesis of myelofibrosis in myeloproliferative disorders","volume":"92","author":"Groopman","year":"1980","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026092411213140600_bib4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"2026092411213140600_bib5","first-page":"5","article-title":"Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2","volume":"3","author":"Agarwal","year":"2016","journal-title":"Stem Cell Investig"},{"issue":"9","key":"2026092411213140600_bib6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"issue":"1","key":"2026092411213140600_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2026092411213140600_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","volume":"35","author":"Ozono","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2026092411213140600_bib9","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"12","key":"2026092411213140600_bib10","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/leu.2017.112","article-title":"Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis","volume":"31","author":"Maekawa","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2026092411213140600_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nri2990","article-title":"Fibrocytes: emerging effector cells in chronic inflammation","volume":"11","author":"Reilkoff","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2026092411213140600_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"2026092411213140600_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"8","key":"2026092411213140600_bib14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2026092411213140600_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026092411213140600_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: a 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"19","key":"2026092411213140600_bib17","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026092411213140600_bib18","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1002\/hem3.70137","article-title":"Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV)","volume":"9","author":"Kiladjian","year":"2025","journal-title":"Hemasphere"},{"issue":"9","key":"2026092411213140600_bib19","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2026092411213140600_bib20","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cam4.1619","article-title":"Safety and efficacy of combination therapy of interferon-\u03b12 and ruxolitinib in polycythemia vera and myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med"},{"issue":"8","key":"2026092411213140600_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41577-021-00500-7","article-title":"RHO GTPases: from new partners to complex immune syndromes","volume":"21","author":"El Masri","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2026092411213140600_bib22","doi-asserted-by":"crossref","first-page":"e42563","DOI":"10.1371\/journal.pone.0042563","article-title":"Rho GTPase expression in human myeloid cells","volume":"7","author":"van Helden","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"2026092411213140600_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/path.5680","article-title":"TGF-\u03b2 as a driver of fibrosis: physiological roles and therapeutic opportunities","volume":"254","author":"Budi","year":"2021","journal-title":"J Pathol"},{"issue":"10","key":"2026092411213140600_bib24","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2026092411213140600_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.2022017097","article-title":"Therapeutic activity of GARP:TGF-\u03b21 blockade in murine primary myelofibrosis","volume":"141","author":"Lecomte","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026092411213140600_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/138945007779940133","article-title":"The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders","volume":"8","author":"Hasselbalch","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"10","key":"2026092411213140600_bib27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res"},{"issue":"3","key":"2026092411213140600_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr Cardiol Rev"},{"issue":"8","key":"2026092411213140600_bib29","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2026092411213140600_bib30","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2026092411213140600_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10245332.1997.11746316","article-title":"Effect of interleukin-1 \u03b1 and interleukin-1 \u03b2 on erythroid progenitor cell growth in serum free cultures: an in vitro study relevant to the pathogenesis of the anemia of chronic disease","volume":"2","author":"Ratajczak","year":"1997","journal-title":"Hematology"},{"key":"2026092411213140600_bib32","first-page":"20","article-title":"A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate","volume":"6","author":"S\u00f8rensen","year":"2016","journal-title":"Leuk Res Rep"},{"issue":"5","key":"2026092411213140600_bib33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00277-024-05693-0","article-title":"The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms","volume":"103","author":"Holik","year":"2024","journal-title":"Ann Hematol"},{"issue":"18","key":"2026092411213140600_bib34","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"key":"2026092411213140600_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.thromres.2018.05.014","article-title":"Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms","volume":"167","author":"Delluc","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"2026092411213140600_bib36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Kre\u010dak","year":"2020","journal-title":"Ann Hematol"},{"issue":"14","key":"2026092411213140600_bib37","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"52","key":"2026092411213140600_bib38","doi-asserted-by":"crossref","first-page":"e2114244118","DOI":"10.1073\/pnas.2114244118","article-title":"Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy","volume":"118","author":"Fernando","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026092411213140600_bib39","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"2026092411213140600_bib40","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026092411213140600_bib41","first-page":"2397","article-title":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia","volume":"111","author":"Reeves","year":"2026","journal-title":"Haematologica"},{"issue":"20","key":"2026092411213140600_bib42","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"S\u00f8rensen","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"2026092411213140600_bib43","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1182\/bloodadvances.2025017016","article-title":"Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"9","author":"Davidsen","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026092411213140600_bib44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2026092411213140600_bib45","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/13\/1723\/2590785\/blood_bld-2025-032693-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/13\/1723\/2590785\/blood_bld-2025-032693-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:25:45Z","timestamp":1790263545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/13\/1723\/569496\/Fibrocytes-drive-JAK2V617F-mutated-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032693","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,24]]},"published":{"date-parts":[[2026,9,24]]}}}